transplant
remain
pioneer
scientif
innov
signific
impact
restor
wellb
patient
benefit
societi
whole
blood
marrow
hematopoiet
stem
cell
becom
accept
instanc
establish
approach
treat
incur
neoplast
diseas
congenit
disord
immun
system
similarli
use
allograft
patient
endstag
organ
diseas
involv
liver
kidney
intestin
heart
lung
provid
possibl
continu
life
potenti
patient
integr
resum
particip
commun
recent
advanc
limb
integu
face
transplant
underscor
substanti
leap
forward
restor
normalci
individu
devast
often
catastroph
physic
encumbr
patient
undergo
solid
organ
transplant
advanc
understand
complex
interplay
within
variou
facet
immun
respons
transplant
allogen
tissu
recipi
immun
system
fail
recogn
self
result
encourag
longterm
outcom
achiev
decod
higher
mammalian
immun
underscor
recent
progress
made
develop
implement
refin
strategi
har
potenti
devast
immun
reject
implant
solid
organ
allograft
antireject
strategi
expect
involv
delic
balanc
favor
preserv
function
allograft
aim
limit
sever
druginduc
suppress
recipi
immun
function
crucial
surveil
variou
neoplast
process
convent
opportunist
infect
similar
albeit
oppos
role
undesir
immun
respons
come
play
patient
undergo
hematopoiet
blood
marrow
stem
cell
transplant
foreign
donor
conflict
aris
aforement
disconnect
immun
recognit
self
versu
nonself
transplant
stem
cell
instal
foreign
effector
immun
cell
recipi
remain
unab
result
graftversushost
diseas
capabl
unleash
potenti
ruinou
system
inflamm
result
irrevers
tissu
damag
death
stem
cell
graft
restor
immun
function
marrow
patient
need
myeloabl
antineoplast
therapi
furthermor
foreign
graftmedi
adapt
cancer
immun
surveil
wide
recogn
pivot
featur
sustain
cancer
remiss
follow
success
allogen
hematopoiet
stem
cell
transplant
featur
stem
cell
graftassist
antitumor
respons
recogn
graftversusleukemia
graftversustumor
effect
donorderiv
adapt
antitumor
immun
import
object
allogen
stem
cell
transplant
especi
patient
hematolog
malign
form
base
donor
lymphocyt
infus
treat
cancer
recurr
posttranspl
period
patient
follow
solid
organ
transplant
recipi
allogen
hsct
antigvhd
therapi
assess
continu
refin
achiev
lowest
possibl
cumul
iatrogen
immun
suppress
requir
prevent
treat
gvhd
wherea
earnest
attempt
made
preserv
recipi
immun
function
risk
convent
opportunist
infect
malign
overwhelm
project
efficaci
feasibl
lifesav
procedur
number
agent
success
use
prevent
treatment
graftversushost
diseas
solid
organ
allograft
reject
sever
immun
dysfunct
instanc
direct
consequ
treatment
agent
commonli
prescrib
combin
drug
regimen
cyclosporin
first
major
breakthrough
regard
subsequ
gener
calcineurin
inhibitor
cni
improv
therapeut
index
although
result
sever
immun
suppress
risk
opportunist
infect
like
cmv
bk
viru
certain
posttranspl
cancer
question
therapeut
feasibl
agent
tacrolimu
especi
patient
low
risk
allograftrel
complic
seriou
infect
due
cytomegaloviru
includ
viremia
endorgan
diseas
bk
viru
viremia
viruria
bk
viru
allograft
nephropathi
risk
potenti
graft
compromis
rare
progress
multifoc
leukoencephalopathi
due
polyomaviru
higher
potenti
opportunist
cancer
kaposi
sarcoma
ebv
lymphoprolif
disord
among
other
wellrecogn
limit
individu
given
tacrolimu
extend
durat
dose
lead
prolong
high
serum
drug
concentr
experi
sirolimu
macrolid
xenobiot
induc
potent
immun
suppress
via
inhibit
mechanist
target
rapamycin
mtor
conserv
threonin
serin
protein
kinas
associ
lower
incid
cmv
infect
solid
organ
transplant
recipi
protect
antivir
effect
mtor
inhibitor
bk
viru
nephropathi
renal
transplant
note
consist
addit
antitumor
properti
mtor
inhibitor
may
favor
influenc
lower
incid
risk
posttranspl
malign
recipi
solid
organ
allograft
especi
profil
indic
low
risk
graft
reject
monoclon
antibodi
bcell
pathway
also
gain
promin
potenti
treatment
option
alemtuzumab
campath
monoclon
antibodi
target
antigen
express
lymphocyt
treatment
campath
result
profound
lymphocyt
deplet
druginduc
immun
suppress
may
last
month
although
maximum
degre
lymphopenia
note
week
therapi
part
hsct
preparatori
condit
regimen
treatment
alemtuzumab
associ
reduc
risk
gvhd
follow
allogen
hematopoiet
stem
cell
transplant
kidney
transplant
recipi
risk
organ
reject
low
patient
given
alemtuzumab
howev
benefit
mainli
observ
patient
low
risk
allograft
reject
trial
underway
aim
explor
regimen
may
spare
cni
tacrolimu
prevent
allograft
reject
human
monoclon
antibodi
rituximab
target
antigen
express
promin
select
b
lymphocyt
form
cornerston
treatment
solid
organ
antibodymedi
renal
allograft
reject
also
consid
standard
care
treatment
posttranspl
bcell
lymphoprolif
disord
system
glucocorticoid
maintain
relev
drug
cocktail
given
prevent
treat
solid
organ
graft
reject
gvhd
sinc
earli
observ
enabl
addit
corticosteroid
success
reduc
cyclosporin
dose
tradit
need
prevent
reject
transplant
allograft
observ
regard
major
breakthrough
forg
path
preserv
transplant
organ
without
seriou
lifethreaten
cni
toxic
detail
discuss
regard
immunosuppress
agent
prevent
treatment
allograft
reject
provid
chapter
throughout
book
keen
understand
patient
underli
immun
defect
knowledg
cornerston
essenti
optim
infect
risk
stratif
assess
need
prevent
preemptiv
empir
antimicrobi
therapi
inform
serv
imper
establish
meaning
patientcent
manag
infect
prevent
paradigm
tabl
provid
outlin
relationship
underli
immun
defect
suscept
particular
group
pathogen
also
import
note
combin
unrel
immun
defect
may
overlap
furthermor
patient
may
present
multipl
infect
concurr
sequenti
close
proxim
primari
infect
episod
varieti
convent
opportunist
microorgan
extens
exposur
hospit
environ
pose
risk
transplant
recipi
acquir
infect
may
respond
convent
antimicrobi
drug
recent
interest
explor
potenti
influenc
perturb
reorgan
host
microbi
flora
microbiota
result
extens
exposur
healthcar
environ
broadspectrum
antimicrobi
drug
among
factor
yield
greater
insight
field
larg
underappreci
decad
alter
orointestin
microbiota
propos
limit
observ
studi
influenc
risk
acquir
infect
recurr
previous
resolv
infect
suboptimum
respons
antimicrobi
therapi
importantli
longterm
viabil
transplant
allograft
possibl
noninfecti
complic
potenti
relationship
alter
host
microbiota
current
investig
import
approach
assess
transplant
patient
lend
understand
knowledg
tempor
relationship
risk
infect
may
occur
variou
clinic
phase
transplant
procedur
tabl
fig
exampl
patient
longstand
chronic
gvhd
addit
risk
infect
often
seen
asplen
patient
function
hyposplen
patient
chronic
gvhd
increas
risk
system
fungal
diseas
like
invas
aspergillosi
herp
viru
reactiv
herald
cmv
viremia
addit
encapsul
bacteria
outlin
tabl
may
also
includ
risk
profil
evalu
patient
patient
receiv
treatment
acut
gvhd
allogen
hsct
heighten
risk
invas
aspergillosi
infect
due
filament
mold
unlik
first
risk
period
invas
mold
diseas
allogen
stem
cell
recipi
coincid
period
preengraft
sever
neutropenia
patient
acut
chronic
gvhd
seldom
neutropen
tabl
illustr
salient
featur
infect
risk
associ
type
stem
cell
graft
pretranspl
condit
preparatori
regimen
drug
commonli
use
prevent
gvhd
cord
blood
stem
cell
regard
major
breakthrough
sourc
yield
steadi
suppli
hematopoiet
stem
cell
especi
among
patient
difficult
find
immunolog
hlamatch
compat
hematopoiet
stem
cell
graft
cord
blood
stem
cell
limit
number
nucleat
cell
adequ
children
adult
due
larger
bodi
surfac
area
transplant
less
optimum
number
stem
cell
complic
posttranspl
period
issu
inadequ
delay
neutrophil
engraft
peripher
blood
cell
count
recoveri
precari
graft
stabil
similar
recipi
tcelldeplet
graft
higher
risk
infect
associ
sever
prolong
neutropenia
observ
gvhd
tabl
variou
strategi
explor
assuag
limit
includ
transplant
cord
blood
graft
one
donor
ex
vivo
expans
singl
donor
cord
blood
graft
increas
yield
nucleat
cell
review
cord
blood
transplant
comprehens
cancer
center
houston
texa
infect
incid
rate
ratio
total
infect
episod
per
day
risk
surviv
cbt
time
higher
adult
patient
compar
children
import
note
risk
infect
even
greater
three
time
higher
adult
neutropenia
time
higher
patient
gvhd
compar
children
undergo
cbt
procedur
consid
essenti
creat
comprehens
infect
assess
strategi
take
account
recogn
local
issu
particular
transplant
unit
uniqu
patient
popul
approach
requir
cogniz
exist
influenc
may
promot
risk
infect
includ
local
region
infect
trend
pattern
pathogen
preval
drug
suscept
profil
continu
vigil
regard
emerg
pathogen
everchang
infect
risk
profil
advanc
transplant
procedur
druginduc
immun
suppress
paramount
import
provid
care
highli
vulner
transplant
popul
varieti
noninfecti
condit
may
clinic
radiograph
emul
infecti
process
among
noninfecti
maladi
involv
skin
lung
great
imit
present
difficult
clinic
distinguish
infect
cellul
pneumonia
two
chapter
volum
dedic
provid
indepth
discuss
topic
approach
establish
correct
diagnosi
opportunist
infect
base
maxim
uncertain
obtain
tissu
sampl
dilig
adjud
central
tenet
establish
accur
diagnosi
immunolog
vulner
patient
procliv
atyp
diseas
present
complic
ascertain
correct
time
diagnosi
inaccur
diagnosi
old
dispens
serolog
culturebas
system
may
lead
inappropri
ineffect
treatment
worsen
patient
morbid
risk
complic
death
therefor
focus
yet
comprehens
differenti
diagnos
encompass
etiolog
infect
noninfecti
caus
may
mimic
infecti
process
includ
limit
drug
toxic
de
novo
malign
post
transplant
cancer
recurr
typic
atyp
present
lymphoprolif
disord
immuneinflammatori
diseas
like
gvhd
tissu
infiltr
process
solid
allograft
reject
among
other
may
greatli
improv
guidanc
optim
manag
approach
patient
undergo
lifesav
stem
cell
solid
organ
allograft
transplant
